Your browser doesn't support javascript.
loading
Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement.
Li, Jian-Jun; Ma, Chang-Sheng; Zhao, Dong; Yan, Xiao-Wei.
Afiliação
  • Li JJ; Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Ma CS; Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
  • Zhao D; Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
  • Yan XW; Beijing Union Medical College Hospital, Beijing, China.
JACC Asia ; 2(6): 653-665, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36444328
Elevated concentration of lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral artery disease, and so on. Emerging data suggest that Lp(a) contributes to the increased risk for cardiovascular events even in the setting of effective reduction of plasma low-density lipoprotein cholesterol. Nevertheless, puzzling issues exist covering potential genetic factors, Lp(a) assay, possible individuals for analysis, a cutoff point of increased risk, and clinical interventions. In the Chinese population, Lp(a) exhibited a distinctive prevalence and regulated various cardiovascular diseases in specific ways. Hence, it is valuable to clarify the role of Lp(a) in cardiovascular diseases and explore prevention and control measures for the increase in Lp(a) prevalence in the Chinese population. This Beijing Heart Society experts' scientific statement will present the detailed knowledge concerning Lp(a)-related studies combined with Chinese population observations to provide the key points of reference.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article